Market Cap 123.24M
Revenue (ttm) 6.65M
Net Income (ttm) -136.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,049.92%
Debt to Equity Ratio 0.00
Volume 3,469,200
Avg Vol 1,704,430
Day's Range N/A - N/A
Shares Out 116.26M
Stochastic %K 18%
Beta 2.19
Analysts Sell
Price Target $4.94

Company Profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 875 1800
Address:
12278 Scripps Summit Drive, San Diego, United States
Rocketman808
Rocketman808 Mar. 20 at 6:00 PM
$FATE watching volume here. like the loading going on down here. massive lots just went through
1 · Reply
Rocketman808
Rocketman808 Mar. 20 at 2:28 PM
$FATE more for the next trip
0 · Reply
Nik7777
Nik7777 Mar. 19 at 5:14 PM
0 · Reply
aw20
aw20 Mar. 19 at 2:35 PM
$FATE grabbed more at 1.04 👀
0 · Reply
Rocketman808
Rocketman808 Mar. 18 at 9:05 PM
$FATE Fate Therapeutics (NASDAQ: FATE) — Off-the-Shelf CAR T as Same-Day Outpatient Therapy $XBI
1 · Reply
Rocketman808
Rocketman808 Mar. 18 at 9:04 PM
$FATE will take the free press from Avai paid article. just hit the newswire. its never bad to be in an article titled $45B and get our same day discharge highlighted! https://stocks.apple.com/ApWsGGI3LQTi4qXegNOGs-w
0 · Reply
Rocketman808
Rocketman808 Mar. 18 at 4:43 PM
$FATE why not, post fed may be smarter but i like this. 1.09 add
0 · Reply
radonco
radonco Mar. 18 at 4:35 PM
$FATE can’t believe this keeps revisiting $1
1 · Reply
aw20
aw20 Mar. 18 at 2:13 PM
$FATE grabbed a starter at 1.10 👀
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Mar. 18 at 1:27 PM
🌅 Watchlist part 3 ✅ $TURB low 3 support, if above 3.30, have potential to 3.50/.80 ✅ $HITI mid 2.50 support, if above 2.85, have potential to 3/3.20 ✅ $BIAF low 2.30 support, if above 2.50, have potential to 2.70/.80 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support. 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance. ⏳⌛ $FATE $ONCY still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D
0 · Reply
Latest News on FATE
Fate Therapeutics to Present at Upcoming Investor Conferences

Feb 14, 2025, 4:01 PM EST - 1 year ago

Fate Therapeutics to Present at Upcoming Investor Conferences


Fate Therapeutics Announces Leadership Transition

Nov 29, 2024, 1:05 PM EST - 1 year ago

Fate Therapeutics Announces Leadership Transition


Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript

May 11, 2024, 6:12 PM EDT - 2 years ago

Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript


Fate Therapeutics: Looking For A Potential Turnaround In 2024

Apr 29, 2024, 12:09 PM EDT - 2 years ago

Fate Therapeutics: Looking For A Potential Turnaround In 2024


Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 8:25 PM EST - 2 years ago

Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript


Fate Therapeutics: Getting There, But Perpetually

Nov 12, 2023, 12:10 PM EST - 2 years ago

Fate Therapeutics: Getting There, But Perpetually


Fate Therapeutics, Inc. (FATE) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 11:37 PM EDT - 2 years ago

Fate Therapeutics, Inc. (FATE) Q2 2023 Earnings Call Transcript


Rocketman808
Rocketman808 Mar. 20 at 6:00 PM
$FATE watching volume here. like the loading going on down here. massive lots just went through
1 · Reply
Rocketman808
Rocketman808 Mar. 20 at 2:28 PM
$FATE more for the next trip
0 · Reply
Nik7777
Nik7777 Mar. 19 at 5:14 PM
0 · Reply
aw20
aw20 Mar. 19 at 2:35 PM
$FATE grabbed more at 1.04 👀
0 · Reply
Rocketman808
Rocketman808 Mar. 18 at 9:05 PM
$FATE Fate Therapeutics (NASDAQ: FATE) — Off-the-Shelf CAR T as Same-Day Outpatient Therapy $XBI
1 · Reply
Rocketman808
Rocketman808 Mar. 18 at 9:04 PM
$FATE will take the free press from Avai paid article. just hit the newswire. its never bad to be in an article titled $45B and get our same day discharge highlighted! https://stocks.apple.com/ApWsGGI3LQTi4qXegNOGs-w
0 · Reply
Rocketman808
Rocketman808 Mar. 18 at 4:43 PM
$FATE why not, post fed may be smarter but i like this. 1.09 add
0 · Reply
radonco
radonco Mar. 18 at 4:35 PM
$FATE can’t believe this keeps revisiting $1
1 · Reply
aw20
aw20 Mar. 18 at 2:13 PM
$FATE grabbed a starter at 1.10 👀
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Mar. 18 at 1:27 PM
🌅 Watchlist part 3 ✅ $TURB low 3 support, if above 3.30, have potential to 3.50/.80 ✅ $HITI mid 2.50 support, if above 2.85, have potential to 3/3.20 ✅ $BIAF low 2.30 support, if above 2.50, have potential to 2.70/.80 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support. 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance. ⏳⌛ $FATE $ONCY still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Mar. 18 at 4:02 AM
🌅 Watchlist part 2 ✅ $HIT.X low $2 support, if above $2.30, have potential to $2.60/$2.70 ✅ $DVLT low $0.80 support, if above $1.00, have potential to $1.20/$1.30 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support. 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance. ⏳⌛ $FATE $ONCY still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D
0 · Reply
Bli1
Bli1 Mar. 17 at 5:07 PM
$FATE https://stocktwits.com/Bli1/message/646825993 10% ago. I never hope a pilote goes down, and I am aware that FATE will once more become a great opp. to make some nice dough
0 · Reply
cta7978
cta7978 Mar. 17 at 2:19 PM
0 · Reply
Nik7777
Nik7777 Mar. 16 at 7:16 PM
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Mar. 15 at 9:52 AM
$FATE First note on their assets. https://substack.com/@biotechpharmainvestor/note/c-228047902?r=2nece1
3 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Mar. 15 at 8:30 AM
$FATE. Large upside if any of their assets works out. 1. Allogeneic 2. iPSC-derived (vs from donors) 3. Relatively low cost 4. Low (or even NO) lymphodepletion regimen needed before administration 5. Outpatient administration 6. Sofisticated combination of multiple gene edits (impractical with in vivo approaches) 7. Both oncology and auto-immune pipeline 8. Multiple PoC data within cash runway (through 2027) 9. Still trading much below cash
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Mar. 15 at 8:16 AM
$FATE. Large upside if any of their assets works out. (1) Allogeneic (2) iPSC-derived (vs from donors) (3) Relatively low cost (4) Low (or even NO) lymphodepletion regimen needed before administration (5) Sofisticated combination of multiple gene edits (impractical with in vivo approaches) (6) Both oncology and auto-immune pipeline (7) Multiple PoC data within cash runway (through 2027) (8) Still trading much below cash
0 · Reply
Rocketman808
Rocketman808 Mar. 13 at 7:59 PM
$FATE closing above the 200 day moving average
0 · Reply
Nik7777
Nik7777 Mar. 13 at 6:29 PM
0 · Reply
GlassIsHalfEmpty
GlassIsHalfEmpty Mar. 13 at 3:42 PM
$IBRX $XBI $IBB $QQQ $FATE This has to be worth billions. Proprietary AI robotic driven mfr bioreactors!
2 · Reply
Nik7777
Nik7777 Mar. 13 at 3:08 PM
1 · Reply
Diefreeandsell
Diefreeandsell Mar. 13 at 3:00 PM
$IBRX $XBI $IBB $QQQ $FATE IBRX Completes Scalable Manufacturing Pathway for M-ceNK Cell Therapy Commercial Scalability: The completion of the NK2022 and NK2023 manufacturing engineering programs established a process that generates up to 5 billion cells from a single collection, yielding 8 to 10 therapeutic doses in just 12 days. This significantly lowers the potential cost of goods (COGS) compared to traditional, less efficient cell therapy manufacturing. By validating cryopreservation from over 60 donors, the company is building a "World Bank" of ready-to-use cells. This allows for an off-the-shelf delivery model, which is essential for achieving the high-volume sales necessary to drive long-term revenue. Readiness for Automation: The methods are now established for use in AI-driven automated robotic systems (NANT Leonardo). This readiness suggests future revenue growth will be supported by a highly efficient, automated production line rather than labor-intensive manual processes.
1 · Reply